Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy After Discontinuing CAB + RPV Injections
2023-506660-13-00Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Primary endpoints: Treatment-emergent Grade 3 or 4 study drug-related adverse events through Week 12 and Treatment-emergent Grade 3 or 4 laboratory abnormalities through Week 12. Started Feb 2024; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2023-506660-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506660-13-00.